Schaier Matthias, Kälble Florian, Benning Louise, Reichel Paula, Mahler Christoph, Nusshag Christian, Rusnak Jonas, Gutting Tobias, Preusch Michael, Zeier Martin, Morath Christian, Speer Claudius
Department of Nephrology, Heidelberg University, INF 162, 69120, Heidelberg, Germany.
Department of Internal Medicine III (Cardiology, Angiology, and Pneumology), Heidelberg University, Heidelberg, Germany.
Rheumatol Int. 2025 Mar 3;45(3):68. doi: 10.1007/s00296-025-05812-8.
The ANCA-associated vasculitis (AAV) has an exceptionally high morbidity and mortality especially in patients with diffuse alveolar hemorrhage (DAH). Data on DAH in elderly AAV patients is still very limited. To investigate the impact of DAH on patient survival, relapse-free survival, death from infectious complications, and the incidence of pneumonia in one of the most vulnerable but often underrepresented AAV subpopulation-elderly patients. We included 139 AAV patients in this retrospective cohort study and performed a 5-year follow-up. AAV patients were divided into patients ≤ 65 and > 65 years ("elderly"). Elderly AAV patients were further subdivided into patients with and without DAH. Relapse-free survival was comparable (P = 0.49) whereas overall patient survival (P = 0.01) was significantly lower in patients > 65 as compared to ≤ 65 years. Death due to infectious complications occurred more frequently in the elderly cohort (log-rank P = 0.02). Especially the incidence of pneumonia (including opportunistic pathogens) was considerably higher in elderly AAV patients (log-rank P = 0.001). Overall survival in elderly patients was significantly lower in patients with as compared to patients without DAH [8/18 (44%) versus 9/52 (17%) deaths (P = 0.02)] while relapse-free survival was again comparable (P = 0.87) between both groups. Notably, 6 out of 8 fatal outcomes in elderly DAH patients were associated with severe infections. In multivariate analyses, age and glucocorticoid (GC) dose at 3 months were the only predictors of death from infectious complications, whereas this could not be independently demonstrated for DAH. Life-threatening infections with (opportunistic) pneumonia are common in elderly AAV patients with DAH during the first 12 months and higher GC dose was an independent predictor of death from infectious complications.
抗中性粒细胞胞浆抗体相关性血管炎(AAV)的发病率和死亡率极高,尤其是在合并弥漫性肺泡出血(DAH)的患者中。关于老年AAV患者DAH的数据仍然非常有限。为了研究DAH对最脆弱但往往未得到充分代表的AAV亚群之一——老年患者的生存、无复发生存、感染性并发症死亡以及肺炎发病率的影响。我们在这项回顾性队列研究中纳入了139例AAV患者,并进行了5年的随访。AAV患者被分为年龄≤65岁和>65岁的患者(“老年患者”)。老年AAV患者进一步分为有DAH和无DAH的患者。无复发生存率相当(P = 0.49),而年龄>65岁的患者与年龄≤65岁的患者相比,总体患者生存率显著更低(P = 0.01)。感染性并发症导致的死亡在老年队列中更频繁发生(对数秩检验P = 0.02)。特别是老年AAV患者肺炎(包括机会性病原体)的发病率相当高(对数秩检验P = 0.001)。与无DAH的患者相比,有DAH的老年患者总体生存率显著更低[死亡人数分别为8/18(44%)和9/52(17%)(P = 0.02)],而两组之间的无复发生存率再次相当(P = 0.87)。值得注意的是,老年DAH患者的8例致命结局中有6例与严重感染有关。在多变量分析中,年龄和3个月时的糖皮质激素(GC)剂量是感染性并发症死亡的唯一预测因素,而DAH无法独立证明这一点。在最初12个月内,患有(机会性)肺炎的危及生命感染在患有DAH的老年AAV患者中很常见,更高的GC剂量是感染性并发症死亡的独立预测因素。